REGENXBIO slumps after serious side effects mar Duchenne gene therapy results

Leave a Comment / By /

Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company’s first quarter earnings call Thursday.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top